Ritonavir
- Generic Name
- Ritonavir
- Brand Names
- Kaletra, Norvir, Paxlovid, Viekira Pak, Ritonavir Mylan
- Drug Type
- Small Molecule
- Chemical Formula
- C37H48N6O5S2
- CAS Number
- 155213-67-5
- Unique Ingredient Identifier
- O3J8G9O825
- Background
Ritonavir is an HIV protease inhibitor that interferes with the reproductive cycle of HIV. Although it was initially developed as an independent antiviral agent, it has been shown to possess advantageous properties in combination regimens with low-dose ritonavir and other protease inhibitors. It is now more commonly used as a booster of other protease inhibi...
- Indication
Ritonavir is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection.
...
- Associated Conditions
- Chronic hepatitis C genotype 1a, Chronic hepatitis C genotype 1b, Human Immunodeficiency Virus Type 1 (HIV-1) Infection, Mild, moderate Novel Coronavirus Infectious Disease (COVID-19)
- Associated Therapies
- -
A Pharmacokinetic Study of Narlaprevir as a Single Dose or With Ritonavir Combination in Patients With Hepatic Impairment and Healthy Matched Volunteers
- First Posted Date
- 2019-02-06
- Last Posted Date
- 2019-05-22
- Lead Sponsor
- R-Pharm
- Target Recruit Count
- 32
- Registration Number
- NCT03832426
- Locations
- 🇬🇪
LLC Chapidze Emergency Cardiology Center, Tbilisi, Georgia
🇬🇪LLC Guli (Heart) - Cardiology clinic, Tbilisi, Georgia
🇷🇺- Institution of the Russian Academy of Sciences "RAS Hospital", Troitsk, Russian Federation
Study of the Efficacy and Safety of Lonafarnib / Ritonavir With and Without Pegylated Interferon -Alfa-2a
- Conditions
- Interventions
- First Posted Date
- 2018-10-25
- Last Posted Date
- 2023-04-14
- Lead Sponsor
- Eiger BioPharmaceuticals
- Target Recruit Count
- 407
- Registration Number
- NCT03719313
- Locations
- 🇺🇸
University of Miami Schiff Center for Liver Disease, Miami, Florida, United States
🇮🇹Azienda Ospedaliero Universitaria di Parma, Parma, Italy
🇮🇹Azienda Ospedaliera Universitaria Policlinico Tor Vergata, Roma, Italy
A Drug-drug Interaction (DDI) Study of Morphothiadine Mesilate/Ritonavir in Healthy Subjects
- First Posted Date
- 2018-09-07
- Last Posted Date
- 2019-10-09
- Lead Sponsor
- Sunshine Lake Pharma Co., Ltd.
- Target Recruit Count
- 56
- Registration Number
- NCT03662568
- Locations
- 🇨🇳
The First Hospital of Jilin University, Changchun, Jilin, China
The Safety, Antiviral Activity, and Pharmacokinetics of Morphothiadine Mesilate Capsules
- First Posted Date
- 2018-08-20
- Last Posted Date
- 2020-07-23
- Lead Sponsor
- Sunshine Lake Pharma Co., Ltd.
- Target Recruit Count
- 20
- Registration Number
- NCT03638076
- Locations
- 🇨🇳
The First Hospital of Jilin University, Changchun, Jilin, China
Treatment of Chronic Delta Hepatitis With Lonafarnib, Ritonavir and Lambda Interferon
- Conditions
- Interventions
- First Posted Date
- 2018-07-26
- Last Posted Date
- 2021-12-14
- Target Recruit Count
- 26
- Registration Number
- NCT03600714
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
A Study to Assess the Effect of Ritonavir on the Single-Dose Pharmacokinetics of JNJ-61393215 in Healthy Participants
- First Posted Date
- 2018-07-20
- Last Posted Date
- 2018-11-09
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 12
- Registration Number
- NCT03593954
- Locations
- 🇺🇸
PRA International, Salt Lake City, Utah, United States
A Drug Interaction Study to Assess the Pharmacokinetics of Narlaprevir and Antiretroviral Drugs
- Conditions
- Interventions
- First Posted Date
- 2018-05-25
- Last Posted Date
- 2019-02-19
- Lead Sponsor
- R-Pharm
- Target Recruit Count
- 36
- Registration Number
- NCT03537404
- Locations
- 🇷🇺
Clinic "Bessalar" JSC, Moscow, Russian Federation
Efficacy and Safety of All-Oral Combination of Narlaprevir/Ritonavir and Daclatasvir in Treatment-Naїve Patients With Chronic Hepatitis C Genotype 1b
- Conditions
- Interventions
- First Posted Date
- 2018-04-02
- Last Posted Date
- 2018-12-19
- Lead Sponsor
- R-Pharm
- Target Recruit Count
- 105
- Registration Number
- NCT03485846
- Locations
- 🇷🇺
FBIS CSRI of Epidemiology of Federal Service on Customers, Moscow, Russian Federation
🇷🇺St. Petersburg SBHI Center of Prevention and Fight against AIDS and Infection Diseases, Saint Petersburg, Russian Federation
🇷🇺SBEI HPE Moscow State Medical and Dental University n.a. A.I. Evdokimov of Ministry of Health of Russia, Moscow, Russian Federation
Study to Evaluate the Efficacy of GS-9131 Functional Monotherapy in Human Immunodeficiency Virus (HIV)-1-Infected Adults Failing a Nucleos(t)Ide Reverse Transcriptase Inhibitor-Containing Regimen With Nucleos(t)Ide Reverse Transcriptase Inhibitor Resistant Virus
- Conditions
- Interventions
- First Posted Date
- 2018-03-21
- Last Posted Date
- 2021-01-05
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 21
- Registration Number
- NCT03472326
- Locations
- 🇿🇼
Joint Research Ethics Committee for the University of Zimbabwe College of Health Sciences and Parirenyatwa Group of Hospitals, Harare, Zimbabwe
🇺🇬Joint Clinical Research Centre, Kampala, Uganda
Study of DS-8201a for Participants With Advanced Solid Malignant Tumors
- Conditions
- Interventions
- First Posted Date
- 2017-12-26
- Last Posted Date
- 2023-12-11
- Lead Sponsor
- Daiichi Sankyo Co., Ltd.
- Target Recruit Count
- 40
- Registration Number
- NCT03383692
- Locations
- 🇯🇵
Hokkaido Cancer Center, Sapporo, Hokkaido, Japan
🇯🇵Hokkaido University Hospital, Sapporo, Hokkaido, Japan
🇯🇵Kobe University Hospital, Kobe, Hyogo, Japan
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.